MedTrace Logo

Individual Patient Compassionate Use of Crenolanib

NCT03620318 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-08-09

No results posted yet for this study

Summary

Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis.

Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)

Conditions

  • FLT3-ITD Mutation
  • FLT3/TKD Mutation
  • PDGFR-Alpha D842V
  • PDGFRA Gene Amplification

Interventions

DRUG

Crenolanib besylate

Sponsors & Collaborators

  • Arog Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620318 on ClinicalTrials.gov